UsAgainstAlzheimer’s Applauds Positive News on Alzheimer’s Drug Aducanumab

Statement from George Vradenburg on the announcement by Biogen and Eisai of plans to seek regulatory approval in early 2020 by the Food and Drug Administration (FDA) for aducanumab, an investigational treatment for early Alzheimer’s disease.

New Study Highlights Need for Healthcare Providers to Engage Alzheimer’s Caregivers

A new study from UsAgainstAlzheimer's and Mayo Clinic spotlights the often-overlooked need for family caregivers of people with Alzheimer’s disease to be more engaged by physicians during medical appointments with their loved ones.

A road map for including Latinos and African Americans in Alzheimer’s research

Alzheimer’s is the only leading cause of death with no current effective treatment or cure. The limited inclusion of communities of color in research will only worsen the outlook, though the success of efforts bubbling up across the country could help us keep pace.

Four former U.S. Surgeons General: Dementia is our top public health crisis

Former U.S. Surgeons General Drs. Richard Carmona, Joycelyn Elders, Antonia Novello & David Satcher call dementia top public health crisis, urge for an annual brain health check-up

More than 180 Health and Alzheimer’s Groups Urge U.S. Task Force to Revise Stance and Encourage Cognitive Screenings

The U.S. Preventive Services Task Force (USPSTF), which makes recommendations about preventive clinical services contended in a draft recommendation that there is “insufficient” evidence to warrant doctors conducting cognitive screening for older adults. Public comments on the task force’s recommendations are due today. Alzheimer’s impact is a societal and economic issue, health advocate says

UsAgainstAlzheimer's and our Chairman George Vradenburg were featured in a piece.

Aducanumab Reversal

Engaging Family Caregivers

Alzheimer's research in communities of color

Dementia is our top public health crisis

UsAgainstAlzheimer’s Warns of Setback to Prevention and Care Article

  • A Letter from Our Chairman

    UsAgainstAlzheimer’s Brain Health Partnership has issued a Call to Action white paper outlining recommendations for building a better system of care to promote brain health and fight back against Alzheimer’s.

Read the Letter

We Are Committed to Stopping Alzheimer's by 2025.

  • Blog Post

    “A Devil of a Disease”: The Current Alzheimer’s Pipeline

    This article was originally published by BioSpace on August 7, 2019.

    By Mark Terry

    As anyone following Alzheimer’s research knows, drug development for the disease has been a wasteland of failed

    Read more
  • Blog Post

    My Birthday Wish

    My name is Andres Martin and this week I turned 32 years old.  I’m a proud father, husband, and veteran. Over the last couple of years, I’ve come to recognize

    Read more
  • Welcome to the New Era of Alzheimer’s Research: How People with Alzheimer’s and Care Partners are Shaping the Future of Drug Development

    This article was originally published by Lundbeck on July 17, 2019.

    By Mark Terry

    Leigh Callahan, PhD, is a respected epidemiologist and outcomes researcher who focuses on rheumatic disease. Her husband,

    Read more

The Pulse of the Community: Volume 4, Fall 2019

The A-LIST transforms the stories of more than 8,000 people living with Alzheimer’s or other dementias into evidence-based insights by providing unique, rapid-response, self-reported data through virtual surveys on what matters most on a wide range of Alzheimer’s-related topics. The A-LIST offers a powerful and validating voice for those living with Alzheimer’s and those caring for them, and a pathway to help expand treatments and accelerate toward a cure.